HCC
WINT

Hirtle Callaghan & Co’s Windtree Therapeutics Inc WINT Stock Holding History

Hirtle Callaghan & Co’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-56
Closed -$1K – 450
2014
Q4 		$1K Buy
+56
New +$1.23K ﹤0.01% 561
2014
Q3 		– Sell
-56
Closed -$1K – 645
2014
Q2 		$1K Hold
56
– – ﹤0.01% 636
2014
Q1 		$2K Hold
56
– – ﹤0.01% 569
2013
Q4 		$2K Hold
56
– – ﹤0.01% 554
2013
Q3 		$2K Buy
56
+40
+250% +$970 ﹤0.01% 564
2013
Q2 		$0 Buy
+16
New +$394 ﹤0.01% 65

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Hirtle Callaghan & Co's WINT Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Windtree Therapeutics Inc (WINT) in Q1 2015, closing a stake of 56 shares — an estimated $1K sold.

Hirtle Callaghan & Co first reported a position in WINT in Q2 2013 and held it in 6 quarters. The position peaked at $2K in Q1 2014. 58 funds tracked by Wall St. Rank hold WINT as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Windtree Therapeutics Inc position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 56 Windtree Therapeutics Inc shares in Q1 2015, an estimated $1K.
  • Hirtle Callaghan & Co first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Windtree Therapeutics Inc position peaked at $2K in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.